CytoDyn (OTC: CYDY)
$0.14
(-1.4%)
-$0.00
Price as of April 26, 2024, 1:27 p.m. ET
CytoDyn Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CytoDyn Company Info
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
News & Analysis
Featured Article
3 Biotechs to Avoid Like the Plague in July
Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.
Zhiyuan Sun | Jul 6, 2021
Featured Article
What's Behind This Wild-Card Coronavirus Stock?
Failure is not an option for this small-cap biotech developing a COVID-19 treatment.
Zhiyuan Sun | Jun 8, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.